Nonsteroidal antiinflamatory drugs are currently one of the most widely used categories of drugs, because there is a huge number of indication for theirs purpose. This huge purpose of this drugs has theirs own price, which is shown in side effects, especialy in the upper parts of gastrointestinal tract: erosions of the mucose in 35-60 %, ulcers in 10-25%, strong bleeding or perforation in <1%. It is appears that this drugs are responsible for 10-20 thousands lethal outcome in the world. Even small dose of acetlisalicil acid by 75 mg,which is used in prevention of cardiovascular disease, brings to the damage of mucose GIT and 11% have ulcer. Inhibition ciklooxigen-1,which have main role in protection mucose of stomach and duodenum on the part of NAIL, lead to damage mucose GIT, and that is the result of sistemic inhibition, which is indenpendant of the way of getting drugs. Some author instigate a local effect of Nail,as week acid. It is necessary to protect highrisk pacient with using gastroprotektiv drugs
F. C, J. C, L. H. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 352:238–44.
2.
D.Y G. Cox-2 inhibitors, other NSAIDs and cardiovascular risk: the seduction of common sense. JAMA. 296:1653–6.
3.
C.J H. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? Aliment Pharmacol Ther. 20(Suppl. 2):59–64.
4.
D.Y G. Guidelines’ or marketing for non-steroidal anti-inflammatory drug and proton pump inhibitor use? Aliment Pharmacol Ther. 19:1323–5.
5.
C. S, I. B, J.F. B. Towards a GI safer anti-inflammatory therapy. Gastroenterology International. 12:186–215.
6.
G.S. G, H. S, C.B. W, P.A N. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol. 18(Suppl 28):11–4.
7.
A.H. S, W.M. W, J. K, D M. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 114:307–13.
8.
R.T. S, R.J V. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 86:449–58.
9.
J.R V. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat New Biol. 231:23–5.
10.
T.M. M, L W. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 361:573–4.
11.
M. O, D. F, D.M P. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
12.
F. C, K.F. T, J. W, M. Y. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet. 359:931–8.
13.
F. C, S. C, U.B. S. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 344:967–73.
14.
Review. Cyclooxygenase-2 implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 49:443–53.
15.
N.M A. Epidemiology and prevention of non-steroidal anti-inflammatory drug effects in the gastrointestinal tract. British Journal of Rheumatology. 34(suppl.1):5–10.
16.
L.A.G R. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med. 104(3A):304–15.
17.
N. M, A. Y, M. H. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol. 87:1183–6.
18.
L.A. GR, A.M. W, S.P G. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology. 3:337–42.
19.
Brooks P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med. 104(3A):913–30.
20.
Damjanov D. Odnos nesteroidnih antiinflamatornih lekova i ulceroznih lezija gornjih segmenata gastrointestinalnog trakta.
21.
A. SM, M.N. K, D. P, N.S. M, S. Đ, Đ Ć. Uloga Helicobacter pylori infekcije i nesteroidnih antiinflamatornih lekova u etiopatogenezi krvarenja iz gornjeg dela gastrointestinalnog trakta. Acta Chir Iugosl. 54(1):51–62.
22.
W.F. S, C. K, M C. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 48:626–32.
23.
F.M. G, S.R. H, A.J K. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 328:131–316.
24.
C.H H. Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J. 137:913–9.
25.
L.K. C, D.Y G. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther. 19:111–9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
